Driving reinvestment in R&D for antibiotics and advocating their responsible use


George Osborne tells us Antibiotic Resistance is on track to be a greater threat to our health than cancer

George Osborne warned delegates at the International Monetary Fund (IMF) in Washington, DC, on 14 April 2016 that antibiotic resistance will become “an even greater threat to mankind than cancer” if the world fails to take action. The Chancellor said that according to evidence from the UK’s Review on Antimicrobial Resistance, antibiotic resistance could claim 10 million lives worldwide by the year 2050 if we, as a global society, fail to act.   Click here to read the full article.    ...
Read more

DRIVE-AB Progress and “Responsible Use of Antibiotics” Preliminary Findings Featured at ECCMID 2016

The DRIVE-AB consortium had a significant presence at this year's European Congress on Clinical Microbiology and Infectious Diseases (ECCMID) 2016 in Amsterdam, being featured at the European Network Corner, the Pipeline Corner and Pipeline Talk, and presenting a numerous abstracts. The consortium presented a poster in the European Network Corner on DRIVE-AB's progress to date. Please click here to see the overview of the project's midterm progress. DRIVE-AB Work Package 1A, ‘Responsible use of antibiotics, new and old’, presented preliminary results at the Congress; one oral presentation and four posters (details below) on quality and...
Read more

First 180 Days Draft Report on the US National Action Plan for Combating Antibiotic-Resistant Bacteria

In consultation with the Secretaries of Defense and Agriculture, the U.S. Department of Health and Human Services (HHS) Secretary’s establishment of the President’s Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) is one of several recent U.S. Government (USG) actions to respond to the threat. As stipulated in Executive Order 13676 and their Charter, the PACCARB advises the HHS Secretary on the programs and policies intended to support the implementation and evaluation of the National Action Plan (NAP) for Combating Antibiotic-Resistant Bacteria (CARB); all written reports created by the PACCARB will then be provided to the President by the HHS Secretary. DRIVE-AB Read more

R&D for Antibiotic Resistance & Infectious Diseases in China Supported by GSK

GlaxoSmithKline (GSK) will put up $29 million for a Beijing-based R&D institute to tackle antibiotic resistance and infectious disease health threats in China by working in tandem with academics and regulators. The Institute for Infectious Diseases and Public Health will draw on 20 in-house GSK researchers to start and will look to existing drugs in the U.K. drugmaker's portfolio as well as clinical trial stage work on HIV and multidrug-resistant bacterial infections, China Daily reported.   Click here to read the full story.    ...
Read more